OTLK / Outlook Therapeutics collapses as FDA rejects application for eye drug

Live audio webcast fireside chat on Tuesday, November 7th at 1:50 PM ET Live audio webcast fireside chat on Tuesday, November 7th at 1:50 PM ET more_horizontal

Live video webcast panel presentation on Tuesday, September 26th at 1:35 PM ET Live video webcast panel presentation on Tuesday, September 26th at 1:3 more_horizontal

Outlook Therapeutics (NASDAQ: OTLK ) stock is taking a beating on Wednesday after getting a rejection letter from the FDA. That letter has to do with more_horizontal

Outlook Therapeutics Inc (NASDAQ:OTLK) stock collapsed, losing some 70% of its value in premarket, after the drug discovery firm's potential treatment more_horizontal

Outlook Therapeutics said on Wednesday the U.S. Food and Drug Administration declined to approve its experimental eye disease drug, in part due to man more_horizontal

Outlook Therapeutics (OTLK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season more_horizontal

ISELIN, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA appr more_horizontal

OTLK is developing an ophthalmic formulation of bevacizumab. There is a logic behind this, and there's also positive data. However, certain developmen more_horizontal